Soar BioDynamics Welcomes Additional Industry Experts to Advisory Board
SAN FRANCISCO – (April 21, 2009) Soar BioDynamics, Ltd., a pioneer in Web-based personalized data-driven health analysis, today announced three new members to its Scientific Advisory Board: Dr. E. David Crawford, Head of Urologic Oncology at University of Colorado, Denver; Dr. Stephen J. Freedland, M.D., Duke University Division of Urologic Surgery, Department of Surgery, Duke Prostate Center; and Dr. Judd W. Moul, M.D., Duke University Prostate Center Director & Division Chief. The Soar Scientific Advisory Board is comprised of the most prominent minds in urology, dedicated to advancing modern healthcare with personalized analysis. Soar BioDynamics launched its Dynamic Screening Service in late March.
"We are being challenged to reevaluate how we diagnose and treat prostate cancer," said Dr. Crawford. "I am pleased to have the opportunity to work with Soar BioDynamics to achieve these goals."
Drs. Crawford, Moul and Freedland join Dr. Christopher J. Kane M.D., Professor of Surgery and Chief of Urology, University of California San Diego and Dr. Georg Bartsch, M.D., Professor and Chair of the Department of Urology at Innsbruck Medical University in bringing extensive experience in advanced research and clinical studies to Soar’s Scientific Advisory Board.
Dr. Freedland added, "I look forward to working with Soar BioDynamics to develop better detection tools for early and more accurate diagnosis of various prostate conditions."
"I have dedicated my career to the research and treatment of prostate conditions with the goal of helping men and their doctors make the best prostate health decisions," said Dr. Moul. "Soar BioDynamics represents the latest trend in healthcare and I am looking forward to participating in this pioneering organization."
About Soar BioDynamics, Ltd.
Soar BioDynamics harnesses the power of advanced mathematical computation to bring bold new perspective to common medical test results with an easy-to-use Web-based system. Dynamic Screening for prostate cancer is Soar's first invention that has been expanded to screening for prostatitis and BPH. Soar Dynamic Prostate Health Analysis can help bring some context to PSA test results and help patients and doctors make more enlightened choices about further tests, referrals or treatments.
For more information regarding Soar BioDynamics, Ltd. or to view a sample report, please visit http://www.soarbiodynamics.com.